

BRINCAT, A., STEWART, D., WEIDMANN, A. and VELLA BONANNO, P. 2018. Patients' lived experiences of cytotoxic medications prescribed for the management of malignant solid tumours: a systematic review. [Protocol]. *PROSPERO* [online], item number CRD42016048457. Available from:
http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42016048457

Patients' lived experiences of cytotoxic medications prescribed for the management of malignant solid tumours: a systematic review. [Protocol]

BRINCAT, A., STEWART, D., WEIDMANN, A. and VELLA BONANNO, P.

2018

Patients' lived experiences of cytotoxic medications prescribed for the management of malignant solid tumours: a systematic review

Citation

Alison Brincat, Derek Stewart, Anita Weidmann, Patricia Vella Bonanno. Patients' lived experiences of cytotoxic medications prescribed for the management of malignant solid tumours: a systematic review. PROSPERO 2016 CRD42016048457 Available from: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42016048457

Review question

The aim of the systematic review is to critically appraise, synthesise and present the available evidence of patients' lived experiences of cytotoxic medications prescribed for the management of malignant solid tumours.

In relation to the patients' pharmacological treatment journey for the management of malignant solid tumours: • What are the patients' lived experience? • What is the medication related burden? • What are the medication related beliefs? • What is the medication taking practice? • What is the relationship between the lived experience and medication related burden, medication related beliefs and medication taking practice?

Searches

Systematic review according to PRISMA guidelines will be conducted in the following databases: CINAHL, MEDLINE, Cochrane Library, Embase, International pharmaceutical abstracts and PsycARTICLES.

Manual searches of related studies listed in the reference, footnote and citations will be carried out to include more relevant papers. The search will be restricted to publications in the English language and will centre on the concepts of patients' lived experience, cytotoxic medications and malignant solid tumours. Concept mapping was applied to develop keywords and generate search terms.

Types of study to be included

All study designs of research studies which have employed any methodological approach including quantitative or mixed methodologies will be included.

Condition or domain being studied

The lived experiences of adult patients prescribed cytotoxic medications for the management of malignant solid tumours.

Participants/population

Inclusion criteria: patients who are 18 years and over irrespective of their gender, ethnicity and stage of disease receiving cytotoxic medications for the management of malignant solid tumours.

Intervention(s), exposure(s)

Articles will be reviewed if they describe the patients' lived experience of cytotoxic medications for the management of malignant solid tumours.

Comparator(s)/control

Not applicable.

Main outcome(s)

The primary outcomes will include the experiences, burden, beliefs and practice of patients in relation to cytotoxic medications.

Additional outcome(s)

None.

Data extraction (selection and coding)

The initial screening of all titles retrieved during the search will be carried out to identify potentially relevant papers. This will be followed by screening of abstracts and then by full paper against the pre-defined systematic review aim, questions and inclusion/exclusion criteria. A random sample of 10% of the retrieved titles and abstracts during the search strategy will be independently checked by two research members for consistency of inclusion/exclusion and enhance the reliability of the process. Any disagreement will be resolved by consensus within the research team; otherwise these will be reported in the final review. Any duplicate publications of the same studies will be eliminated and the number of duplicates will be recorded using Prisma 2009 flow diagram.

Qualitative and quantitative data extraction will be conducted using standardised data extraction tools. These will be developed so as to obtain specific information pertinent to the review aim and questions.

Risk of bias (quality) assessment

Quality assessment will be conducted on all included manuscripts by two independent reviewers using established critical appraisal tools. Disagreements will be resolved by consensus after discussion with the research team.

Strategy for data synthesis

Research findings will be analysed using narrative and meta-synthesis approach.

Analysis of subgroups or subsets

None planned

Contact details for further information

Ms Brincat

a.brincat@rgu.ac.uk

Organisational affiliation of the review

Robert Gordon University, Aberdeen Scotland

Review team members and their organisational affiliations

Ms Alison Brincat. School of Pharmacy and Life Sciences, Robert Gordon University, Aberdeen Scotland

Professor Derek Stewart. School of Pharmacy and Life Sciences, Robert Gordon University, Aberdeen Scotland

Dr Anita Weidmann. School of Pharmacy and Life Sciences, Robert Gordon University, Aberdeen Scotland

Dr Patricia Vella Bonanno.

Type and method of review

Systematic review

Anticipated or actual start date

01 October 2016

Anticipated completion date

28 February 2017

Funding sources/sponsors

The project will be funded by the 'Get Qualified Scheme' upon successful completion of the doctorate course.

Conflicts of interest

None known

Language

English

Country

Scotland

Stage of review

Review Completed not published

Subject index terms status

Subject indexing assigned by CRD

Subject index terms

Antineoplastic Agents; Disease Management; Humans; Neoplasms

Date of registration in PROSPERO

27 September 2016

Date of first submission

30 July 2018

Stage of review at time of this submission

Preliminary searches	Yes	Yes
Piloting of the study selection process	Yes	Yes
Formal screening of search results against eligibility criteria	Yes	Yes
Data extraction	Yes	Yes
Risk of bias (quality) assessment	Yes	Yes
Data analysis	Yes	Yes

The record owner confirms that the information they have supplied for this submission is accurate and complete and they understand that deliberate provision of inaccurate information or omission of data may be construed as scientific misconduct.

The record owner confirms that they will update the status of the review when it is completed and will add publication details in due course.

Versions

27 September 2016

08 August 2018